Skip to main content

Table 2 Gene Mutation Frequencies in Pre-treatment Tissue Biopsies

From: Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer

Gene

Subset of Subjects with Pre-Treatment Tissue Biopsies (N = 47)

TP53

20 (42.6)

KRAS

12 (25.5)

KEAP1

9 (19.1)

BRAF

6 (12.8)

STK11

5 (10.6)

ERBB2

5 (10.6)

EGFR

2 (4.2)

  1. Data are n (%)